Prosecution Insights
Last updated: May 29, 2026

Examiner: GROOMS, TIFFANY NICOLE

Tech Center 1600 • Art Units: 1636 1637 1699

This examiner grants 59% of resolved cases

Performance Statistics

58.8%
Allow Rate
-1.2% vs TC avg
217
Total Applications
+45.3%
Interview Lift
1301
Avg Prosecution Days
Based on 177 resolved cases, 2023–2026

Rejection Statute Breakdown

2.3%
§101 Eligibility
6.1%
§102 Novelty
50.7%
§103 Obviousness
7.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
16989119 Large Gene Excision and Insertion Non-Final OA President and Fellows of Harvard College
17631240 COMPOSITIONS AND METHODS FOR TREATING ALPHA THALASSEMIA Non-Final OA THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
18303533 SITE SPECIFIC GENETIC ENGINEERING UTILIZING TRANS-TEMPLATE RNAS Non-Final OA Massachusetts Institute of Technology
18310044 GATA6-AS1 lncRNA FOR USE IN THERAPY Non-Final OA Ramot At Tel-Aviv University Ltd.
18392854 COMPOSITIONS COMPRISING A LECITHIN CHOLESTEROL ACYLTRANSFERASE VARIANT AND USES THEREOF Non-Final OA The Trustees of the University of Pennsylvania
18322675 SYSTEMS, METHODS, AND COMPOSITIONS FOR RNA-GUIDED RNA-TARGETING CRISPR EFFECTORS Non-Final OA The University of Tokyo
18247157 MARF/MFN MODULATORS AND USES THEREOF Non-Final OA University of Massachusetts
18295387 CRISPR/CAS9 COMPLEX FOR GENOMIC EDITING Non-Final OA THE UAB RESEARCH FOUNDATION
17911130 GENE INTERFERENCE VECTOR- AND IRON NANOPARTICLE-BASED COMPOSITION FOR KILLING CANCER CELLS, AND USE THEREOF Non-Final OA SOUTHEAST UNIVERSITY
18658840 YEAST STRAINS WITH SELECTED OR ALTERED MITOTYPES AND METHODS OF MAKING AND USING THE SAME Non-Final OA Wisconsin Alumni Research Foundation
17782897 CLINICAL DECISION SUPPORT FOR PERSONALIZED ADAPTIVE PROSTATE CANCER THERAPY Final Rejection H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.
18220070 PREVENTION OR TREATMENT OF WASTING SYNDROME Non-Final OA City of Hope
18424838 DUAL-FUNCTIONAL COSMETIC COMPOSITION AND PREPARING METHOD THEREOF Non-Final OA UBIPROTEIN CORP
17780002 CONSTRUCTS, COMPOSITIONS AND METHODS THEREOF HAVING IMPROVED GENOME EDITING EFFICIENCY AND SPECIFICITY Final Rejection DANMARKS TEKNISKE UNIVERSITET
17776993 Method for Detecting Undifferentiated Cells Final Rejection Eiken Kagaku Kabushiki Kaisha
18307000 COMPOSITIONS AND METHODS FOR MODULATING GENE TRANSCRIPTION NETWORKS Final Rejection Nuclear RNA Networks, Inc.
18007255 COMBINED THERAPY AGAINST CANCER Non-Final OA FUNDACIÓ INSTITUT HOSPITAL DEL MAR D'INVESTIGACIONS MÈDIQUES (IMIM)
18006075 BIOMARKER SPECIFIC FOR LIVER CANCER, AND USE THEREOF Non-Final OA NEORNAT

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month